Evidence map›Paper›PMID 23073467›Full record

ArticleTransplantation2012

Associations of ABCB1 and IL-10 genetic polymorphisms with sirolimus-induced dyslipidemia in renal transplant recipients.

Wai-Johnn Sam, Christine E Chamberlain, Su-Jun Lee, Joyce A Goldstein, Douglas A Hale, Roslyn B Mannon, Allan D Kirk, Yuen Yi Hon

Abstract read
In one paragraph

Article in Transplantation, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
0.6field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 13 citations in OpenAlex.

  1. Effects ofCurrent pharmaceutical design · 2024
    Pooled it
  2. Article
  3. Article
  4. Review
  5. Review
  6. Role of pharmacogenomics in dialysis and transplantation.Current opinion in nephrology and hypertension · 2014
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Wai-Johnn SamClinical Center Pharmacy Department, National Institutes of Health, Bethesda, MD 20892, USA.
Christine E Chamberlain
Su-Jun Lee
Joyce A Goldstein
Douglas A Hale
Roslyn B Mannon
Allan D Kirk
Yuen Yi Hon
National Institutes of Health Clinical Center · USEmory University · USUniversity of Alabama at Birmingham · US

Funding

Drug Metabolizing Enzymes In Humans And Animal ModelsZIAES021024 · NIEHS · NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES · PI GOLDSTEIN, JOYCE · 2009 to 2015
$11.0M
Influence of MDR/CYP Genotypes on Sirolimus PK/PD in Renal Transplant PatientsZIACL005097 · CLC · CLINICAL CENTER · PI HON, CHRISTINE · 2009 to 2012
$0k
Intramural NIH HHS ZIA CL005097NIEHS NIH HHS Z01ES02124
6 · The paper itself

Abstract

backgroundHyperlipidemia is a common adverse effect of sirolimus (SRL). We previously showed significant associations of ABCB1 3435C>T and IL-10 -1082G>A with log-transformed SRL dose-adjusted weighted-normalized trough. We further examined to see whether these polymorphisms were also associated with SRL-induced dyslipidemia.

methodsGenotyping was performed for ABCB1 1236C>T, 2677 G>T/A, and 3435C>T; CYP3A4 -392A>G; CYP3A5 6986A>G and 14690G>A; IL-10 -1082G>A; TNF -308G>A; and ApoE ε2, ε3, and ε4 alleles. The longitudinal changes of total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), and triglyceride (TG) levels after SRL treatment before statin therapy were analyzed by a linear mixed-effects model, with adjustments for selected covariates for each lipid.

resultsUnder the dominant genetic model, ABCB1 3435C>T was associated with TC (P=0.0001) and LDL-C (P<0.0001) values after SRL administration. Mean TC and LDL-C levels were 26.9 and 24.9 mg/dL higher, respectively, in ABCB1 3435T carriers than 3435CC homozygotes at an average SRL trough concentration of 4 ng/mL without concomitant medication. ABCB1 1236C>T under the recessive model and IL-10 -1082G>A under the dominant model were associated with log-transformed TG values (P=0.0051 and 0.0436, respectively). Mean TG value was 25.1% higher in ABCB1 1236TT homozygotes compared with ABCB1 1236C carriers and was 12.4% higher in IL-10 -1082AA homozygotes than -1082G carriers.

conclusionsABCB1 polymorphisms were found to be associated with lipid responses to SRL treatment, confirming the role of ABCB1 gene in SRL pharmacokinetics and pharmacodynamics. Further studies are necessary to define the role of ABCB1 and IL-10 polymorphisms on SRL-induced dyslipidemia in renal transplantation.

Indexed as

AdultAgedATP Binding Cassette Transporter, Subfamily BATP Binding Cassette Transporter, Subfamily B, Member 1Cholesterol, LDLDose-Response Relationship, DrugDyslipidemiasFemaleGenotypeGraft RejectionHumansImmunosuppressive AgentsInterleukin-10Kidney TransplantationLinear ModelsLongitudinal StudiesABCB1 protein, humanATP Binding Cassette Transporter, Subfamily BATP Binding Cassette Transporter, Subfamily B, Member 1Cholesterol, LDLImmunosuppressive AgentsInterleukin-10SirolimusTriglycerides

Identifiers

PMID23073467
PMCPMC3491093
OpenAlexW1992309730

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.